Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - amiloride hydrochloride (unii: fzj37245uc) (amiloride - unii:7dzo8eb0z3), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amiloride hydrochloride 5 mg - amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. the use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. this fixed combination drug is not indicated for the initial therapy of ed

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - methyldopa - film-coated tablet - 250 milligram(s) - methyldopa; methyldopa (levorotatory)

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - methyldopa - film-coated tablet - 500  milligram(s) - methyldopa; methyldopa (levorotatory)

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

h.j. harkins company, inc. - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - diethylpropion hydrochloride 75 mg - pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (see precautions). agitated states. patients with a history of drug abuse. use in combination with other anorectic agents is contraindicated. during or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. diethylpropion hydrochloride extended release tablets, 75 mg are schedule iv controlled substances. diethylpropion hydrochloride has some chemical and pharmacologic similarities to the amphetamines and other related stimulant drugs that have been extensively abused. there have been reports of subjects becoming psychologically dependent on diethylpropion. the possibility of abuse should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. abuse of amphetamines and related drugs may be associated with varying degrees of psychologic dep

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

greenstone llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 1 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 5 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride for oral suspension is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (ldl) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [ldl] cholesterol) who do not respond adequately to diet. generally, colestipol hydrochloride for oral suspension has no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considered in patients with severe elevations of ldl-c or with definite chd. according to the ncep guidelines, the goal of treatment is to lower ldl-c, and ldl-c is to be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. the ncep treatment guidelines are shown below. ldl-cholesterol mg/dl (mmol/l) definite atherosclerotic disease* two or more other risk factors** initiation level goal no no ≥ 190 (≥ 4.9) < 160 (< 4.1) no yes ≥ 160 (≥ 4.1) < 130 (< 3.4) yes yes or no ≥ 130 (≥ 3.4) ≤ 100 (≤ 2.6) * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** other risk factors for coronary heart disease (chd) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c < 35 mg/dl (0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥ 60 mg/dl (1.6 mmol/l). colestipol hydrochloride for oral suspension is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 1 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

greenstone llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 5 g in 5 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride granules are indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (ldl) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [ldl] cholesterol) who do not respond adequately to diet. generally, colestipol hydrochloride granules have no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried o

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepril hydrochloride and h

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

apotex corp. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepril hydrochloride and